Compare GBX & OMER Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GBX | OMER |
|---|---|---|
| Founded | 1974 | 1994 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Railroads | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.3B | 1.3B |
| IPO Year | 1996 | 2008 |
| Metric | GBX | OMER |
|---|---|---|
| Price | $37.46 | $16.69 |
| Analyst Decision | Sell | Buy |
| Analyst Count | 3 | 3 |
| Target Price | ★ $45.33 | $27.50 |
| AVG Volume (30 Days) | 289.6K | ★ 1.2M |
| Earning Date | 10-26-2026 | 11-12-2026 |
| Dividend Yield | ★ 3.52% | N/A |
| EPS Growth | 28.02 | ★ 98.15 |
| EPS | ★ 2.21 | 0.77 |
| Revenue | ★ $3,240,200,000.00 | $29,868,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $8.54 | $73.59 |
| P/E Ratio | ★ $17.58 | $20.94 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $37.61 | $6.24 |
| 52 Week High | $59.19 | $21.24 |
| Indicator | GBX | OMER |
|---|---|---|
| Relative Strength Index (RSI) | 29.88 | 34.83 |
| Support Level | $37.61 | $10.82 |
| Resistance Level | $43.90 | $19.81 |
| Average True Range (ATR) | 1.00 | 0.80 |
| MACD | 0.07 | -0.41 |
| Stochastic Oscillator | 33.83 | 6.26 |
Greenbrier Companies Inc supplies equipment and services to international freight transportation markets, designing and marketing freight railcars in North America, Europe, and Brazil through subsidiaries and joint ventures. It provides railcar wheel services, parts, maintenance, and conversion services in North America. The company owns a lease fleet sourced mainly from its manufacturing operations and offers railcar management, regulatory compliance, and leasing services to railroads and owners. It operates two segments: Manufacturing and Leasing & Fleet Management, with the majority of revenue from Manufacturing. The company operates in the U.S. and internationally, with the majority of revenue from the U.S. market.
Omeros Corp is an inventive, commercial-stage biotechnology company that discovers and develops first-in-class protein and small-molecule therapeutics for large-market and orphan indications, with particular emphasis on complement-mediated diseases, cancers, and addictive or compulsive disorders. The company's clinical-stage development programs include: narsoplimab, its antibody targeting mannan-binding lectin-associated serine protease 2 (MASP-2), the effector enzyme of the lectin pathway of complement; OMS1029, its long-acting antibody targeting MASP-2; and OMS527, its phosphodiesterase 7 (PDE7) inhibitor program.